Swiss Life Sciences Stock News

Clariant (SWX:CLN) just posted its FY 2025 numbers with first half revenue of CHF 1,981 million and basic EPS of CHF 0.08, setting a cautious tone against a backdrop of trailing 12 month revenue of CHF 3,915 million and a basic EPS loss of CHF 0.23. The company has seen revenue hold in a tight band from CHF 2,070 million in the first half of 2024 to CHF 2,082 million in the second half of 2024, alongside EPS moving from CHF 0.48 to CHF 0.26. This now feeds into a mixed margin picture for...

European Commission grants marketing authorization for Ranluspec, a Sandoz biosimilar for major retinal diseases, with a planned European launch in the second half of 2026. US FDA approves an expanded label for Enzeevu, adding new retinal indications to Sandoz Group's ophthalmology offering. Both moves reinforce Sandoz Group's focus on biosimilars in eye care and broaden its addressable market in ophthalmology. Sandoz Group (SWX:SDZ) is leaning further into its biosimilar focus, with...

Dividend affirmation and new medium term plan draw fresh attention Graubündner Kantonalbank (SWX:GRKP) has affirmed an annual dividend of CHF 47.50 per share, with the payout set for 17 March 2026, following its 2025 results and the introduction of a new plan for 2026 to 2030. See our latest analysis for Graubündner Kantonalbank. At a share price of CHF 2,070.00, Graubündner Kantonalbank has posted a 14.36% 90 day share price return and an 18.45% 1 year total shareholder return, suggesting...

Adecco Group (SWX:ADEN) has proposed three new nominees for its Board of Directors: Tobias Knechtle, Matthias Rebellius, and Jacques Sanche. Two longstanding board members, Kathleen Taylor and Didier Lamouche, are planned to step down from their roles. The changes represent a significant shift in board composition for one of the world's largest staffing firms. Adecco Group, listed in Switzerland under SWX:ADEN, operates at the center of global staffing, recruitment, and workforce solutions...

Galderma Group (SWX:GALD) has put fresh clinical data for Nemluvio front and center, as new results from the long term OLYMPIA extension study in prurigo nodularis refocus investor attention on its therapeutic dermatology portfolio. See our latest analysis for Galderma Group. At a share price of CHF145.9, Galderma’s recent OLYMPIA data and Restylane device approval arrive after a 1 year total shareholder return of 32.93%, even as the year to date share price return sits at an 8.87% decline...

OC Oerlikon (SWX:OERL) has drawn fresh attention after reporting a full year 2025 net loss of CHF 19 million, while its board proposed a total dividend of CHF 0.85 per share, including a one time extraordinary payout. See our latest analysis for OC Oerlikon. At a share price of CHF4.23, OC Oerlikon has seen strong short term momentum, with a 30 day share price return of 18.16% and a 90 day share price return of 33.95%, even though the 5 year total shareholder return of 46.83% loss shows a...

Alcon (SWX:ALC) is moving ahead with its pending acquisition of LENSAR, Inc., which is currently under review by the U.S. Federal Trade Commission. The company is also rolling out TOTAL30 Multifocal for Astigmatism contact lenses across the U.S., targeting patients with presbyopic astigmatism. These developments focus on cataract treatment technology and an eye care segment with limited alternatives and high drop out rates. Alcon, trading at around CHF66.86 per share, is involved in several...

Cembra Money Bank (SWX:CMBN) packed several shareholder relevant updates into its 2025 results announcement, pairing higher net income with fresh 2026 guidance, a higher regular dividend, an extra payout and a CFO transition. See our latest analysis for Cembra Money Bank. At a share price of CHF99.6, Cembra Money Bank has paired a modest 7 day share price return of 3.27% with a 90 day share price return of 4.90%. The 1 year total shareholder return of 7.59% and 3 year total shareholder return...

What the latest earnings mean for Walliser Kantonalbank Walliser Kantonalbank (SWX:WKBN) has just reported full year 2025 earnings, with net income of CHF 85.87 million compared with CHF 90.47 million a year earlier, a result that can shape how investors reassess the stock. See our latest analysis for Walliser Kantonalbank. At a share price of CHF143.0, Walliser Kantonalbank has seen a 9.58% 90 day share price return and a 28.36% 1 year total shareholder return, suggesting recent momentum has...

Georg Fischer (SWX:GF) is back in focus after its 2025 results showed lower net income and sales, higher earnings per share from continuing operations, a confirmed dividend, and an increased focus on Flow Solutions. See our latest analysis for Georg Fischer. At a share price of CHF48.78, Georg Fischer has seen pressure in the short term, with a 1 day share price return of 3.69% decline and a 1 year total shareholder return of 28.19% decline. This suggests that recent earnings, the Flow...

Zurich Insurance Group (SWX:ZURN) has put income and earnings firmly in focus by pairing full year 2025 results with an annual dividend of CHF 30.00 per share, payable on 14 April 2026. See our latest analysis for Zurich Insurance Group. The CHF 580.60 share price has moved higher over the past month with a 1 month share price return of 6.45%, while longer term total shareholder returns of 2.97% over 1 year and 93.42% over 5 years suggest steadily rewarded holders. This points to firm but...

Swiss Prime Site (SWX:SPSN) has issued a CHF 350,000,000 zero coupon convertible green bond to refinance existing liabilities and fund eligible sustainable real estate projects within its established framework. See our latest analysis for Swiss Prime Site. The CHF146.70 share price sits against a strong recent run, with a 13.72% 1 month share price return and a 23.80% 3 month share price return, while the 1 year total shareholder return of 45.64% and 3 year total shareholder return of 106.08%...

If you are wondering whether Novartis shares are still reasonably priced at around their current level, this article walks through what the numbers say about value so you can judge for yourself. With the stock at about US$130.50 and returns of 3.2% over 7 days, 14.3% over 30 days, 20.3% year to date, 38.4% over 1 year, 94.4% over 3 years and 109.0% over 5 years, many investors are asking whether the recent performance already reflects the key positives. Recent coverage around Novartis has...

Swiss Re (SWX:SREN) is back in focus after reporting a record 2025 profit, along with plans for higher dividends and a sizeable share buyback program, moves that have sharpened market attention on the stock. See our latest analysis for Swiss Re. The record 2025 profit, higher dividend plans and new share buyback have coincided with a 1 month share price return of 11.34% and a 3 day rebound that contrasts with a 90 day share price return decline of 3.96%, while the 5 year total shareholder...

Intershop Holding FY 2025 results set up a mixed earnings story for investors Intershop Holding (SWX:ISN) has put fresh numbers on the table, with first half FY 2025 revenue of CHF 48.6m and basic EPS of CHF 19.08, against a backdrop of trailing twelve month revenue of CHF 119.1m and EPS of CHF 23.09. The company has seen revenue move from CHF 42.7m in the first half of 2024 to CHF 66.3m in the second half of 2024 and then CHF 48.6m in the first half of 2025, while basic EPS shifted from CHF...

ABB (SWX:ABBN) is expanding its robotics operations in China, with a focus on Automated Guided Vehicles (AGVs) for warehousing and manufacturing. The company is integrating AI and Industry 4.0 technologies into its AGV offerings to support rising automation needs. This expansion reflects ABB's efforts to increase its presence in China's automation and robotics markets. ABB builds robotics and automation solutions for industries that are looking to improve throughput, safety and consistency...

Holcim AG has released its full-year 2025 results, reporting sales of CHF 15,724 million versus CHF 16,201 million in 2024 and net income of CHF 13.18 billion compared with CHF 2.93 billion, alongside sharply higher basic earnings per share of CHF 23.85. The contrast between lower sales and very large growth in net income and earnings per share suggests significant non-operational or one-off effects that investors will want to unpack on the 2025 earnings call held on 27 February 2026. We’ll...

Sandoz Group (SWX:SDZ) just wrapped up FY 2025 with second half revenue of US$5.9b, basic EPS of US$1.25 and net income of US$537m. The company has seen revenue move from US$5.3b and a net loss of US$150m in the second half of 2024 to US$5.3b and net income of US$377m in the first half of 2025, before reaching US$5.9b and EPS of US$1.25 in the latest period. This has set up a full year where trailing 12 month net income stands at US$914m and EPS at US$2.12. With a trailing net profit margin...

Feintool International Holding (SWX:FTON) has kicked off FY 2025 with first half revenue of CHF 334.5 million and a basic EPS loss of CHF 0.34, alongside a net income loss of CHF 5.0 million. The company has seen recent half year revenue move from CHF 390.1 million in the first half of 2024 to CHF 329.5 million in the second half of 2024 and now CHF 334.5 million in the first half of 2025, while EPS shifted from a loss of CHF 0.22 to a loss of CHF 2.78 and now a loss of CHF 0.34. This sets up...

Bystronic (SWX:BYS) has opened FY 2025 with first half revenue of CHF304.6 million and a net income loss of CHF12.9 million, keeping the focus squarely on how quickly the group can turn its earnings profile around. The company has seen revenue move from CHF330.9 million in the first half of 2024 to CHF317.4 million in the second half of 2024 and then to CHF304.6 million in the first half of 2025. Net income losses shifted from CHF20.8 million to CHF46.8 million and then to CHF12.9 million...

Roche Holding (SWX:ROG) received FDA acceptance of its New Drug Application for giredestrant in advanced breast cancer. The filing seeks approval for giredestrant in combination therapy for patients with metastatic breast cancer previously treated with CDK4/6 inhibitors. Roche reported positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, a rare kidney disease. Roche, a global pharmaceuticals and diagnostics group, is closely watched for its late stage pipeline...

UBS Group (SWX:UBSG) has announced a series of leadership changes, with new Board nominees Agustín Carstens and Luca Maestri, several long serving directors stepping down, and Lisa Golia taking charge of US wealth management advisers. See our latest analysis for UBS Group. These boardroom changes come as UBS Group’s share price sits at CHF32.01, with a 1 month share price return of 12.95% decline and a year to date share price return of 16.14% decline, even though the 1 year total shareholder...

If you are wondering whether Julius Bär Gruppe is fairly priced or offering value right now, the key is to look past the share price and focus on what different valuation methods are actually saying. The stock most recently closed at CHF 65.60, with returns of a 0.5% decline over 7 days, 2.1% over 30 days, a 0.3% decline year to date, 14.3% over 1 year, 21.5% over 3 years and 47.2% over 5 years. This gives you a mix of shorter term softness and longer term gains to weigh. Recent coverage of...

Avolta (SWX:AVOL) has secured the duty free concession at Shanghai Pudong Terminal 1, a rare win for an international travel retailer in mainland China that reshapes investor attention on its China exposure. See our latest analysis for Avolta. The Shanghai Pudong win comes at a time when Avolta’s CHF51.95 share price has a 30 day share price return of 10.63% and a 90 day share price return of 17.75%. Its 1 year total shareholder return of 30.73% contrasts with a 5 year total shareholder...